Brief: Syngene International Concludes Acquisition Of Biologics Manufacturing Facility From Stelis Biopharma

Syngene International

01/12/2023 14:33

Dec 1 (Reuters) - Syngene International Ltd  SYNN.NS :
    * CONCLUDES ACQUISITION OF BIOLOGICS MANUFACTURING FACILITY
FROM
STELIS BIOPHARMA
    * ACQUISITION OF UNIT 3 BIOLOGICS MANUFACTURING FACILITY
CONCLUDED
AT REVISED GROSS VALUE OF 6.17 BILLION RUPEES
    * REDUCTION IN GROSS VALUE REFLECTS RETENTION OF EQUIPMENT
NOT
CURRENTLY INSTALLED IN FACILITY BY STELIS BIOPHARMA
    * ACQUISITION WILL ADD 20,000 LITRES OF INSTALLED BIOLOGICS
DRUG
SUBSTANCE MANUFACTURING CAPACITY FOR SYNGENE

Source text for Eikon:  ID:nBSE8x5lB6 
Further company coverage:  SYNN.NS 

 ((Reuters.Briefs@thomsonreuters.com;))